Abken, Hinrich

Identification of a myofibroblast-specific expression signature in skin wounds

Bergmeier, V., Etich, J., Pitzler, L., Frie, C., Koch, M., Fischer, M., Rappl, G., Abken, H., Tomasek, J. J., & Brachvogel, B. (2018) · Matrix Biology

Wound Healing and TreatmentsDermatologic Treatments and Research

Cited by 87

Regression of metastatic melanoma by targeting cancer stem cells

Schlaak, M., Schmidt, P., Bangard, C., Kurschat, P., Mauch, C., & Abken, H. (2012) · Oncotarget

Cancer Cells and MetastasisCutaneous Melanoma Detection and Management

Cited by 71

Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells

Holzinger, A., & Abken, H. (2022) · Pharmacology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 24

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop

Harrer, D. C., Schenkel, C., Bezler, V., Kaljanac, M., Hartley, J., Barden, M., Pan, H., Holzinger, A., Herr, W., & Abken, H. (2022) · Cells

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 24

Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma

Aleksandrova, K., Leise, J., Priesner, C., Aktas, M., Apel, M., Assenmacher, M., Bürger, I., Richter, A., Altefrohne, P., Schubert, C., et al. (2024) · Frontiers in Immunology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 15

Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β Release

Harrer, D. C., Eder, M., Barden, M., Pan, H., Herr, W., & Abken, H. (2024) · Cancers

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1